drugset
Drugs / barecetamab
last change Apr 2025 re-read 3 minutes ago

barecetamab

also known as ISU104

Monoclonal antibody targets ERBB3

Developed for
cancer
Investigated by
ISU Abxis Co., Ltd.

Trials 1

today NCT03552406 · Ph 1
201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT03552406 Apr 2018 → Oct 2020 cancer ISU Abxis Co., Ltd. Unknown No outcome recorded

News releases announcing trial results or a regulatory action · 1

DateIssuerRelease
2025-04-02 Y Biologics Inc. Results [뉴스] "CAR-T 잡아라"…K-바이오, CAR-NK 신약개발 삼매경 ybiologics.com ↗
실험 결과, 이 CAR-NK 세포를 유방암 세포주에 처리했을 때 암세포가 사멸되는 것을 확인했다.

All press releases naming this drug 1 release

DateIssuerRelease

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as barecetamab “A phase Ia/Ib study of novel anti-ErbB3 monoclonal antibody, barecetamab (ISU104) in refractory solid cancers and monotherapy or in combination with cetuximab in recurrent or...” PMID 37357950 ↗ Jun 2023
Known as ISU104 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03552406 ↗
Modality Monoclonal antibody “novel anti-ErbB3 monoclonal antibody” PMID 37357950 ↗ Jun 2023
Route Intravenous “Intravenous Infusion for 1 hour.” NCT03552406 ↗
Target ERBB3 “Targeting ERBB3” NCT03552406 ↗